Veradermics (MANE) Accumulated Expenses (2024 - 2026)

Veradermics (MANE) posted Accumulated Expenses of $5.6 million for Q1 2026, down 19.67% on a QoQ basis from $7.0 million in Q4 2025.

Veradermics (MANE) Accumulated Expenses (2024 - 2026) Analysis & Trends

Veradermics' Accumulated Expenses history runs 3 years deep, the most recent figure standing at $5.6 million for Q1 2026.

Quarterly Accumulated Expenses changed N/A year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (changed N/A YoY) and the FY2025 annual result came in at $7.0 million, up 182.55% from the prior year.
Accumulated Expenses was $5.6 million for Q1 2026 at Veradermics, down from $7.0 million in the prior quarter.
Across five years, Accumulated Expenses topped out at $7.0 million in Q4 2025 and bottomed at $2.5 million in Q4 2024.
A 3-year average of $5.0 million and a median of $5.6 million in 2026 frame the typical range for Accumulated Expenses.
Peak annual rise in Accumulated Expenses reached 182.55% in 2025, while the deepest fall reached 182.55% in 2025.
Veradermics' Accumulated Expenses stood at $2.5 million in 2024, then jumped by 182.55% to $7.0 million in 2025, then decreased by 19.67% to $5.6 million in 2026.
Business Quant data shows MANE's Accumulated Expenses at $5.6 million in Q1 2026, $7.0 million in Q4 2025, and $2.5 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Veradermics	2.63 Bn	2.63 Bn	-

Download Data